In October 2010, Phenomix Corporation went out of business. Phenomix Corporation, a biopharmaceutical company, engaging in the discovery, development, and commercialization of small-molecule product candidates. Its product candidate included PHX1149, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. The company's product candidate also includes PHX1766, which is a protease inhibitor for the treatment of hepatitis C virus infection. It focused its small-molecule drug discovery efforts on enzyme targets, including proteases, kinases, and polymerases. Phenomix Corporation was founded in 2001 and is headquartered in San Diego, California.